+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients



Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients



Neurological Sciences 39(2): 373-376



The role of myeloid cells in the pathogenesis of MS is determined by the polarization they acquire after activation, and mediated by release of extracellular vesicles (MVs). We assessed the effects of treatments for MS on activation and polarization of myeloid cells. MVs levels and markers of polarization of myeloid cells have been assessed at baseline and up to 6 months after the start of a MS treatment. Patients had higher levels of MVs than controls, and these increased significantly over 6 months under natalizumab. Interferon β-1a significantly decreased M1 pro-inflammatory marker IL1β and upregulated Trem2, a receptor important for debris clearance; both interferon β-1a and fingolimod decreased pro-inflammatory marker IL6. Current treatments for MS significantly modulate myeloid cells activity.

(PDF emailed within 0-6 h: $19.90)

Accession: 058427313

Download citation: RISBibTeXText

PMID: 29185135

DOI: 10.1007/s10072-017-3176-2


Related references

Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovascular Therapeutics 32(2): 33-39, 2014

Can we discontinue disease-modifying treatments in multiple sclerosis patients? Yes. Revue Neurologique 173(1-2): 38-40, 2016

Can we discontinue disease-modifying treatments in multiple sclerosis patients? No. Revue Neurologique 173(1-2): 41-43, 2016

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Preference and Adherence 13: 261-272, 2019

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Multiple Sclerosis 14(3): 399-405, 2008

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Bmc Neurology 13: 138, 2014

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab. Multiple Sclerosis and Related Disorders 12: 82-87, 2017

Characteristics of Patients With Relapsing Remitting Multiple Sclerosis (Rrms) Taking Injectable and Oral Disease Modifying Treatments (Dmt) In Europe (Eu). Value in Health 18(7): A766, 2015

Comparison of Patients With Relapsing Remitting Multiple Sclerosis (Rrms) Treated With Disease Modifying Treatments (Dmt) In Europe (Eu) And The United States (Us). Value in Health 18(7): A766, 2015

Characteristics of Patients with Relapsing Remitting Multiple Sclerosis Taking Injectable and Oral Disease Modifying Treatments in the United States. Value in Health 17(7): A404-A405, 2014

Adoption of Oral Disease Modifying Treatments to Manage Patients with Relapsing Remitting Multiple Sclerosis from 2011-2013 in the United States. Value in Health 17(7): A405, 2014

Disease-modifying treatments in multiple sclerosis. La Revue du Praticien 49(17): 1882-1889, 1999

Disease Modifying Treatments for Multiple Sclerosis. Cns Drugs 11(2): 133-157, 1999

Update on disease-modifying treatments for multiple sclerosis. Clinical Therapeutics 36(12): 1938-1945, 2016

Cancer and multiple sclerosis in the era of disease-modifying treatments. Journal of Neurology 258(7): 1304-1311, 2011